Engineering News

UCB Licenses Sepracor U.S. patents for antihistamine Levocetirizine
Thursday February 23, 1:07 am ET

BRUSSELS, BELGIUM--(MARKET WIRE)--Feb 23, 2006 -- BRUSSELS (Belgium) and MARLBOROUGH, Mass. (USA), February 23, 2006 -- UCB S.A. (EURONEXT: UCB) and Sepracor Inc. today announced a licensing agreement relating to the antihistamine levocetirizine. Under this agreement, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding levocetirizine and royalties will be payable to Sepracor on U.S. sales of levocetirizine products.

Under a separate agreement, Sepracor currently earns royalties from UCB on sales of levocetirizine in European countries where the product is sold. Levocetirizine is marketed by UCB under the brand names XYZAL® and XUSAL(TM) in the European Union for treatment of symptoms of seasonal and perennial allergic rhinitis, persistent allergic rhinitis, and chronic idiopathic urticaria (CIU, also known as hives of unknown cause) in adults and children aged 6 years and older.

"Sepracor is pleased to extend its licensing arrangement for levocetirizine to the United States. UCB has built a successful antihistamine franchise worldwide and we are optimistic about the opportunity UCB has to expand it with the introduction of levocetirizine in the U.S.," stated Timothy J. Barberich, Chairman and Chief Executive Officer of Sepracor.

"We are very excited about our new licensing relationship with Sepracor in the United States and the prospect of expanding our antihistamine business," stated Roch Doliveux, Chief Executive Officer of UCB.

About UCB

UCB ( www.ucb-group.com ) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceuticals and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8,500 people in over 40 countries, UCB achieved revenues of EUR 2.1 billion (including net sales, royalties, and fees) in 2004. UCB is listed on the Euronext Brussels Exchange (UCB / UCBBt.BR / UCB BB) with a market capitalization of approximately EUR 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.

About Sepracor

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical compound candidates with a focus on respiratory and central nervous system disorders. Sepracor's corporate headquarters are located in Marlborough, Massachusetts.

Source: UCB

Engineering News Archive

 
// CAREER RESOURCES

Applicant Procedures
Job Seekers
Resume Help
Professional Organizations
Engineering Career Information
Engineering Colleges

// WHAT WE DO
Recruiters for
Professionals in the Chemical
& Pharmaceutical Industries
We recruit exclusively for Engineers and Operations/Maintenance Management Personnel in the following areas:
Specialty chemicals
Bulk chemicals
Commodity Chemicals
Petrochemicals
Fine chemicals
Agrochemicals
Industrial gases
Surfactants
Fertilizers
Solvents
Coatings
Polymers
Pharmaceuticals
Refinery
Career Center | FAQs | Privacy
SESI Corporate Headquarters (954)755-3121 ext 109
© Search Enterprises, Inc. All rights reserved.
Industry News Career Center FAQs Submit a Job About Search Enterprises Submit a Resume Candidates Job Opportunities Search Enterprises Home